Phosphorylation Regulates OLIG2 Cofactor Choice and the Motor Neuron-Oligodendrocyte Fate Switch  by Li, Huiliang et al.
Neuron
ArticlePhosphorylation Regulates OLIG2 Cofactor Choice
and the Motor Neuron-Oligodendrocyte Fate Switch
Huiliang Li,1 Joana Paes de Faria,1 Paul Andrew,1 Justyna Nitarska,2 and William D. Richardson1,*
1Wolfson Institute for Biomedical Research and Research Department of Cell and Developmental Biology
2MRC Laboratory for Molecular Cell Biology
University College London, Gower Street, London WC1E 6BT, UK
*Correspondence: w.richardson@ucl.ac.uk
DOI 10.1016/j.neuron.2011.01.030Open access under CC BY license.SUMMARY
A fundamental feature of central nervous system
development is that neurons are generated before
glia. In the embryonic spinal cord, for example,
a group of neuroepithelial stem cells (NSCs) gener-
ates motor neurons (MNs), before switching abruptly
tooligodendrocyteprecursors (OLPs).Weaskedhow
transcription factor OLIG2 participates in this MN-
OLP fate switch. We found that Serine 147 in the
helix-loop-helix domain of OLIG2 was phosphory-
lated during MN production and dephosphorylated
at the onset of OLP genesis. Mutating Serine 147 to
Alanine (S147A) abolished MN production without
preventing OLP production in transgenic mice,
chicks, or cultured P19 cells. We conclude that
S147 phosphorylation, possibly by protein kinase A,
is required for MN but not OLP genesis and propose
that dephosphorylation triggers the MN-OLP switch.
Wild-type OLIG2 forms stable homodimers, whereas
mutant (unphosphorylated) OLIG2S147A prefers to
form heterodimers with Neurogenin 2 or other bHLH
partners, suggesting amolecular basis for the switch.
INTRODUCTION
All the neurons and glial cells of the mature central nervous
system (CNS) are generated by neuroepithelial stem cells
(NSCs) in the ventricular zone (VZ) that surrounds the lumen of
the embryonic neural tube (forerunner of the spinal cord and
brain). Cell diversification occurs in stages. First, a neurogenic
prepattern is laid down in the plane of the VZ, under the action
of graded morphogens released from organizing centers within
or outside the neural tube. This leads to a mosaic of molecularly
distinct progenitor domains, each of which goes on to generate
a characteristic subset of neurons and glia. Superimposed on
this spatial pattern is a temporal pattern of cell generation from
some regions of the VZ. For example, in the developing cerebral
cortex, different classes of projection neuron are generated in
sequence (Shen et al., 2006); these settle in stereotypic positions
to generate the layered structure of the cortex. Subsequently,
cortical NSCs start to produce glial lineages (astrocytes and918 Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc.oligodendrocytes [OLs]). This late neuron-glial switch is a general
property of NSCs in all parts of the developing brain and spinal
cord. In some areas of the VZ, NSCs switch from neuron to astro-
cyte production, whereas other regions generate oligodendro-
cyte precursors (OLPs), which migrate widely before differenti-
ating into myelin-forming OLs (Rowitch, 2004; Richardson
et al., 2006). Less is known about the temporal control of cell
fate than the spatial patterning that precedes it. We set out to
study this temporal aspect of cell diversification, focusing on
neuron-glial switching in the ventral spinal cord.
Spatial pattern in the ventral half of the developing spinal cord
is established largely through theactionofSonic hedgehog (SHH)
protein released from the notochord and floor plate at the ventral
midline. SHH activates or inhibits different sets of transcription
factors at different distances from the floor plate (different
concentrations of SHH). Subsequently, cross-repressive interac-
tions among the transcription factors expressed in adjacent
regions of the VZ establish sharp boundaries of gene expression
in the dorsal-ventral axis, establishing a set of ribbon-like NSC
domains that run parallel to one another along the neuraxis. In
theventral half of thecord, thesedomainsare known (fromventral
to dorsal) as p3, pMN, p2, p1, and p0 (Jessell, 2000). Six addi-
tional NSC domains (dP1–dP6, dorsal to ventral) are formed in
the dorsal half of the spinal cord under the influence of BMPs
and WNTs secreted from the roof plate (Helms and Johnson,
2003).NSCs in the ventral pMNdomaingenerate several different
subtypes of motor neuron (MN) before switching abruptly to OLP
production (reviewed by Richardson et al., 2000). NSCs in the
neighboring p3 and p2 domains generate interneurons followed
by astrocytes (Rowitch et al., 2002).
The pMN domain contributes all of the MNs and 80% of the
OLPs in the mouse spinal cord (Fogarty, 2006; Richardson et al.,
2006). The remaining OLPs are generated outside pMN in
a SHH-independent manner (Cai et al., 2005; Fogarty et al.,
2005; Vallstedt et al., 2005). pMN is marked by transcription
factor OLIG2 and its close relative OLIG1, which were originally
identified in screens for OL-specific genes (Lu et al., 2000; Take-
bayashi et al., 2000; Zhou et al., 2000). OLIG2 knockout results in
loss of the pMN domain and consequently complete absence of
spinal MNs (Lu et al., 2002; Takebayashi et al., 2002; Zhou and
Anderson, 2002; Park et al., 2002). All spinal OL lineage cells
are lost as well because OLIG2 is required for OLP development
regardless of whether they are generated within or outside of
pMN (Lu et al., 2002; Takebayashi et al., 2002; Zhou and Ander-
son, 2002; Park et al., 2002). In contrast, OLIG1 has a relatively
Figure 1. OLIG2 Is Phosphorylated on S147
(A) In vitro [33P] incorporation assay. Cell lysates of Olig2-transfected Cos-7 cells were immunoprecipitated with rabbit anti-Myc, separated by SDS-PAGE, and
stained with Coomassie blue (left panel). The gel was dried and autoradiographed (right panel). OLIG2 bands are indicated (arrowheads).
(B) Sequence alignment of bHLH domain of OLIG2 and its relatives. A predicted PKA phosphorylation motif containing S147 (black box) was found in the OLIG1/2
bHLH domain (helix 2) of different species. Hs, Homo sapiens; Mm,Mus musculus; Rn, Rattus norvegicus (brown rat); Gg, Gallus gallus (chicken); Dr, Danio rerio
(zebrafish).
(C–F) Transfected Cos-7 cells were analyzed by 2D PAGE followed by WB with anti-Myc antibody: (C) Myc-tagged OLIG2WT; (D) OLIG2S147A; (E) OLIG2WT with
dnPKA; and (F) OLIG2WT lysate treated with CIAP.
(G and H) OLIG2-S147 was phosphorylated in vivo. Mouse spinal cord homogenates from different developmental stages were analyzed by IP with goat anti-
OLIG2, followed by WB with (G) rabbit anti-OLIG2 or (H) rabbit anti-OLIG2 ph-S147.
See also Figure S1 and Table S1.
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OLIG2 Phosphorylation and the Neuron-Glial Switchmild impact on normal development (Lu et al., 2002; J.P.d.F., N.
Kessaris, W.D.R., and H.L., unpublished data; but see Xin et al.,
2005). However, OLIG1 is believed to be crucial for OL regener-
ation in demyelinating diseases such asmultiple sclerosis (Arnett
et al., 2004).
TheOLIGgeneproducts aremembers of a large family of helix-
loop-helix (HLH) transcription factors, which also includes pro-
neural proteins Neurogenin1/2 (NGN1/2) and MASH1/ASCL1
as well as cell lineage regulators MYOD and NEUROD. OLIG2
interactswith different protein partners to regulate specific devel-
opmental processes. It can form heterodimers with NGN2 to
control MN differentiation, and it can bind NKX2.2 to promote
OLP generation and/or differentiation (Novitch et al., 2001;
Zhou et al., 2001; Qi et al., 2001; Sun et al., 2003; Lee et al.,
2005). It can also complex with SOX10 or ZFP488 to regulate
OLP differentiation and enhance myelin gene expression (Wang
et al., 2006; Wissmuller et al., 2006; Li et al., 2007).
Given thecentral roleofOLIG2 inbothMNandOLdevelopment,
we were keen to discover how this one transcription factor canspecify two quite different cell types and especially how it partici-
pates in the MN-OLP temporal fate switch. We present evidence
that OLIG2 controls the switch by reversible phosphorylation on
Serine147 (S147), a predictedprotein kinaseA (PKA) target; phos-
phorylation at this site is required for patterning of the ventral neu-
roepithelium and MN specification, whereas dephosphorylation
favors OLP specification. S147 phosphorylation also causes
OLIG2 to switch its preferred dimerization partner from OLIG2
(or OLIG1) to NGN2. We propose that this regulated exchange of
cofactors is required for and triggers the MN-OLP fate switch.
RESULTS
OLIG2 Is Reversibly Phosphorylated on Serine 147
OLIG2 is rich in serine and threonine residues (50 serines and 14
threonines out of a total of 323 amino acids; see Table S1 avail-
able online), suggesting that it might possess multiple serine/
threonine phosphorylation sites. To test this, we transfected
aMyc epitope-tagged OLIG2 expression vector into Cos-7 cells,Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc. 919
Figure 2. S147A Mutation Alters the Dimerization
Properties of OLIG2
(A) Cos-7 cells were cotransfected with expression
constructs encoding Myc-tagged OLIG2WT or OLIG2S147A
together with V5-tagged OLIG2, OLIG1, NGN2, or SOX10.
Cell lysates were immunoprecipitated with rabbit anti-
Myc, followed by WB with anti-V5. In parallel, one-twen-
tieth of each cell lysate was subjected directly to WB
with anti-OLIG2.
(B–E) Luciferase assay using cell lysates of transfected
Cos-7 cells. The amounts of transfected DNA were
normalized with pCDNA empty vector; Renilla Luciferase
activity was used to calibrate transfection efficiency.
Results are displayed as fold-increase of firefly Luciferase
activity compared to controls (mean ± SEM of three inde-
pendent experiments).
See also Figure S2.
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OLIG2 proteins by immunoprecipitation (IP) with anti-Myc
followed by polyacrylamide gel electrophoresis (PAGE). Two
major radioactive OLIG2 bands were visible (Figure 1A). Separa-
tion of Olig2-transfected Cos-7 cell lysates by two-dimensional
(2D) PAGE (pH gradient in the second dimension) followed by
Western blotting (WB) confirmed thatOLIG2wasphosphorylated
on multiple sites and that most of the phosphates could be
removed by calf intestinal alkaline phosphatase (CIAP) (Figures
1C and 1F). Bioinformatic analysis of OLIG2 using online services
NetPhos 2.0 Server (Blom et al., 1999) and NetPhosK 1.0 Server
(Blom et al., 2004) identified one potential PKA and one potential
protein kinaseC (PKC) phosphorylation site (TableS1). Alignment
of OLIG2 protein sequences from different species revealed that
the predicted PKA site (R[R/K]X[S/T]) (X, any amino acid)—at
S147 in the bHLH Helix-2 (H2) domain—is conserved during
evolution (Figure 1B). This site is also conserved in OLIG1 but
not in NGN1–3 or other bHLH proteins examined. We mutated
S147 to Alanine (S147A), transfected the mutant (Olig2S147A)
and wild-type (Olig2WT) constructs into Cos-7 cells, and visual-
izedOLIG2proteins by2DPAGEandWBasbefore. This revealed
an altered phosphorylation pattern of OLIG2S147A (Figure 1D),920 Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc.indicating that S147 is a bone fide phosphate
acceptor. Moreover, cotransfection of Olig2WT
with a plasmid encoding a dominant-negative
formof PKA (dnPKA) strongly reduced the phos-
phoprotein signal in the low pH range of the 2D
gel (the region affected by S147A mutation),
implying that OLIG2 can be phosphorylated by
PKA on several sites, including S147 (Figure 1E).
OLIG2-S147 Is Phosphorylated In Vivo
during MN Development
To examine OLIG2-S147 phosphorylation status
directly,we raisedanantiserum in rabbits against
a custom phosphopeptide and purified an anti-
body fraction that specifically recognizes the
S147-phosphorylated form of OLIG2 (anti-
OLIG2 ph-S147; Figure S1). We prepared nuclear
extracts of embryonic day 9.5 (E9.5), E11.5, andE13.5mousespinal cord tissue, immunoprecipitatedendogenous
OLIG2 proteinwith a goat anti-OLIG2 antibody, and visualized the
precipitates by PAGE and WB with either rabbit anti-OLIG2 or
rabbit anti-OLIG2 ph-S147. OLIG2 was expressed more or less
equally at all stages examined (Figure 1G). The specific phosphor-
ylated form OLIG2 ph-S147 was present at E9.5 and to a lesser
extent at E11.5 (3.2-fold decrease; see Experimental Proce-
dures) but was not detected at E13.5 (Figure 1H). These results
demonstrate that endogenous OLIG2 is phosphorylated on
S147 during MN production (E9–12) but is later dephosphory-
lated, coinciding with the switch from MN to OLP production
that occurs around E12.5 in mice (Pringle et al., 1996; Richardson
et al., 2006).
Mutation of S147 to Alanine Changes the Protein
Binding Properties of OLIG2
Given the location of the S147 phosphorylation site in the bHLH
domain, it seemed likely that the phosphorylation status of this
site might affect the interactions of OLIG2 with other proteins or
with DNA. OLIG2 can form strong homodimers with itself as well
as heterodimers with OLIG1 but forms weak heterodimers
with other bHLH proteins, such as E12 or NGN2 (Lee
Figure 3. Construction and Characterization of OLIG2S147A Trans-
genic Mice
(A) The OLIG2 open reading frame in a mouse Olig2 PAC was modified to
contain a single mutation Serine147 / Alanine and a downstream V5-tag
(Olig2S147A). A V5-tagged wild-type sequence was made as a control
(Olig2WT). (B) Identification of single-copy transgenic founders by Southern
blot. The transgene band was normalized to the endogenous Olig2 band;
founders whose transgene band was less intense than the endogenous
band carried one copy of the Olig2 transgene.
(C and D) Transgenic embryos expressed OLIG2 faithfully in the ventral spinal
cord. Transverse sections of E11.5 spinal cords from Olig2WT (C) and
Olig2S147A (D) transgenic embryos were coimmunolabeled with OLIG2 (red)
and the V5 epitope (green).
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bHLH transcription factors, including SOX10, NKX2.2, and ZFP488
(Li et al., 2007; Sun et al., 2003;Wang et al., 2006;Wissmuller et al.,
2006).Wecompared thecofactor-bindingproperties ofOLIG2S147A
and OLIG2WT by coIP assays in transfected Cos-7 cells and found
that, compared to OLIG2WT, OLIG2S147A had a reduced ability to
form OLIG2-OLIG2 and OLIG2-OLIG1 dimers, whereas binding to
NKX2.2, SOX10, or MASH1 was unaffected (Figures 2A and S2A).
In contrast, OLIG2S147A complexed more readily with NGN2 (Fig-
ure 2A). Together, these experiments indicate that S147Amutation
does not destabilizeOLIG2or grossly affect its structure but, never-
theless, alters its binding to transcriptional partners.
We tried to mimic constitutive phosphorylation by mutating
S147 to glutamic acid (E) or aspartic acid (D). However, both
OLIG2S147EandOLIG2S147Dexhibited reducedhomodimer forma-
tion just like OLIG2S147A (data not shown). This sort of effect is not
unique to OLIG2. For example, phosphorylation/dephosphoryla-
tion of serine/threonine residues of the bHLH transcription factor
HAND1 have been shown to regulate homodimer versus hetero-
dimer formation, phosphorylation favoring heterodimers of
HAND1 and E proteins and dephosphorylation favoring HAND1
homodimers (Firulli et al., 2003). However, mutation of the key
serine/threonine phosphate acceptors to aspartic acid did not
inhibit HAND1 homodimer formation, as would have been
expected if these substitutions had mimicked constitutive phos-
phorylation, but instead strengthened homodimer formation just
like serine/threonine/ alanine substitution (Firulli et al., 2003).
We also compared the binding properties of OLIG2WT and
OLIG2S147A using a mammalian two-hybrid system (CheckMate
System, Promega) (Figures 2B–2E). This is a bipartite assay that
depends on the physical association of test and target proteins at
the promoter of a Luciferase reporter gene in Cos-7 cells, so acti-
vating Luciferase expression, which can be quantified by chemilu-
minescence.Thisassayconfirmed the resultsof co-IP,namely, that
association of OLIG2WT with an OLIG2S147A target was strongly
reduced relative to either an OLIG2WT or OLIG1 target (Figures 2B
and 2C). In contrast, and also in agreement with the co-IP data,
association of NGN2 with OLIG2S147A was enhanced (Figure 2D).
Furthermore, cotransfection of the catalytic subunit of PKA
enhanced formation of OLIG2-OLIG2 and OLIG2-OLIG1 dimers
while inhibiting OLIG2-NGN2 dimer formation, whereas a dnPKA
had the opposite effect (Figures 2B–2E). In summary, phosphoryla-
tion of OLIG2 on S147, possibly by PKA, has a dramatic effect on
cofactor choice, favoring NGN2 over other potential partners.
In addition we assessed the DNA binding activities of OLIG2WT
and OLIG2S147A by electrophoretic mobility shift assay (EMSA).
OLIG2S147A exhibited significantly weaker binding to the HB9/
M100Ebox (Lee et al., 2005) compared toOLIG2WT (Figure S2B).
Given that dimerization is needed for bHLH proteins to bind to
DNA targets (Murre et al., 1989), this result most likely reflects
the reduced efficiency of OLIG2 homodimer formation as a result
of S147A mutation.
OLIG2S147A Mutant Mice
In order to study the phenotypic consequences of OLIG2-S147
phosphorylation in vivo, we generated Olig2S147A mutant mice.
We modified OLIG2-coding sequence in an Olig2 PAC clone
(not containing Olig1), introducing the S147A mutation whilesimultaneously adding a V5 epitope tag to the C terminus (Fig-
ure 3A). Transgenicmicewere generated by pronuclear injection.
V5-tagged Olig2S147A and Olig2WT mice were made in parallel
and single-copy founders of both lines were selected for further
study (Figure 3B). Immunofluorescence microscopy confirmed
that the Olig2S147A and Olig2WT PAC transgenes were faithfully
expressed in the embryonic spinal cords of both lines (Figures
3C and 3D). We subsequently removed the endogenous Olig2
alleles by crossing the PAC transgenes into an Olig2 null back-
ground (Lu et al., 2002), thereby obtaining single-copyOlig2S147A
andOlig2WT lines (i.e.,Olig2S147A:Olig2/andOlig2WT:Olig2/).
For some experiments we also bred the PAC transgenics with
Olig1/Olig2 double-null mice (Zhou and Anderson, 2002), which
express green fluorescent protein (GFP) under transcriptional
control of Olig2 (see below).
Olig2S147A Mice Lack the pMN Precursor Domain
in the Ventral VZ
Progenitors in p3, the ventral-most progenitor domain of the
embryonic spinal cord, express the transcription factorNeuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc. 921
Figure 4. Ventral Patterning and MN Generation
Are Disrupted in Olig2S147A Mice
The pMN progenitor domain normally occupies the gap
between PAX6 (red) and NKX2.2 (blue) immunolabeling
in the ventral spinal cord of E11.5 embryos (A and C).
pMN was missing in both Olig2 null and Olig2S147A mice
(B and D). MNswere immunolabeled with anti-HB9 (green)
in the Olig2WT spinal cord (F) but were absent in Olig2 null
(E) and Olig2S147A (G). OLIG2S147A protein (red) was still
expressed in Olig2S147A mice (G).
(H–M) Olig2 expression constructs were electroporated in
the HH12–14 chick neural tube. Electroporated cells were
visualized 24 hr later by GFP immunolabeling (green).
Ectopic HB9 expression (red) was induced by Olig2WT
(H–J, white arrow), but not Olig2S147A (K–M).
See also Figure S3.
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a high level of PAX6 (Briscoe et al., 2000). The pMN domain lies
between p3 and p2 and is marked by expression of OLIG2 and
a low level of PAX6 (Lu et al., 2000; Zhou et al., 2000; Figure 4A).
OLIG2 is essential for establishing and maintaining the pMN
domain through cross-regulatory interactions with transcription
factors in neighboring domains. For example, OLIG2 represses
expression of Irx3 and Pax6 ; in the absence of OLIG2 function,
Irx3 and Pax6 are derepressed in pMN, which takes on the char-
acter of p2, generating V2 interneurons and astrocytes instead of
MNs and OLPs (Lu et al., 2002; Zhou and Anderson, 2002) (Fig-
ure 4B). This can be regarded as a ‘‘homeotic’’ transformation
pMN / p2. We found that the pMN domain specifically was
missing in our Olig2S147A mice (Figures 4C and 4D). Moreover,
in Olig2S147A:Olig2 GFP/, Olig1+/ embryos, most pMN precur-
sors (marked by GFP) were observed to adopt a p2 fate (high
PAX6 expression) (Figure S3). These findings demonstrate that
mutation of the S147 phosphate acceptor site destroys the neu-
roepithelial ‘‘patterning’’ function of OLIG2.
Development of MNs Requires S147-Phosphorylated
OLIG2
It is known that MNs fail to develop in the spinal cords ofOlig2/
embryos as a consequence of losing the pMNprogenitor domain
(Lu et al., 2002; Takebayashi et al., 2002; Zhou and Anderson,922 Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc.2002; Figure 4E). Similarly, our Olig2S147A
mutant mice failed to generate MNs, judging
by the lack of expression of the MN-specific
HD transcription factor HB9 (Figure 4G). HB9-
positive MNs developed normally in Olig2WT
mice (Figure 4F). It has been shown previously
that forcing ectopic expression of Olig2 in chick
neural tube by electroporation at Hamilton-
Hamburger (HH) stage12–14 can induce
ectopic production of HB9-positive MNs by
48 hr post-electroporation, mainly in the p2
domain (Novitch et al., 2001; Mizuguchi et al.,
2001; Lee et al., 2005). We confirmed this ability
of Olig2WT to induce ectopic MNs (Figures 4H–
4J) but found that Olig2S147A was inactive in
this regard (Figures 4K–4M). Taken together,the data strongly suggest that S147 phosphorylation is neces-
sary for the MN-inducing function of OLIG2.
S147 Phosphorylation Is Dispensable
for the OL-Inducing Activity of OLIG2
In the spinal cords of Olig2 null mice, expression of the OLP
markers PDGFRa and SOX10 is completely absent (Lu et al.,
2002; Takebayashi et al., 2002; Zhou and Anderson, 2002),
demonstrating an essential role for OLIG2 in OL lineage specifi-
cation. In our Olig2S147A mutant mice, SOX10- and PDGFRa-
expressing OLPs were missing at E14.5 (Figures 5A–5D) but
appeared later at E18.5, though in reduced numbers (15%)
relative to Olig2WT controls (Figures 5E, 5F, 5H, and 5I). At the
time of their first appearance, OLPs were scattered through all
regions of the cord, not concentrated in the ventral cord as in
wild-type mice. This is consistent with the demonstrated loss
of the ventral pMN domain (Figure 4)—the source of most but
not all OLPs in the cord—and suggests that S147 phosphoryla-
tion is not required for OLP specification from other progenitor
domains that do not rely on the prior neuroepithelial patterning
function of OLIG2. We further investigated the effect of S147
phosphorylation on OLP differentiation into myelin-forming OLs
by culturing primary E18.5 spinal cord cells under conditions
permissive for OL differentiation. (It was not possible to study
OL differentiation in vivo since Olig2S147A mutants die at birth
Figure 5. OL Specification in Olig2S147A and Olig2WT Mice
OL lineage cells were marked by SOX10 or PDGFRa immunolabeling (red).
OLPs were present in Olig2WT mice at E14.5 (A and C), but not in Olig2S147A
mice (B and D). At E18.5, SOX10- and PDGFRa-positive OLPs were detected
in spinal cords of Olig2S147A mice (F, F0, I, and I0), though in reduced numbers
compared toOlig2WT controls (E, E0, H, and H0). No OLPs whatsoever were de-
tected in Olig2 null mice (G, G0, J, and J0 ).
(E0–G0) and (H0–J0) are high-magnification views of the areas marked in (E)–(G)
and (H)–(J), respectively.
(K–N)Olig2 expression constructs together with a GFP expression vector were
electroporated into HH12–14 chick neural tubes, and electroporated cells
were visualized 48 hr later by GFP immunolabeling (green). Ectopic Sox10
expression (blue, arrows) was induced by transfected Olig2S147A (M and N),
but not by Olig2WT (K and L).
Scale bars, 80 mm (A–D); 50 mm (E–J0); 100 mm (K–N). See also Figure S4.
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formed in these mutant cell cultures as in wild-type cultures,
demonstrating that S147 phosphorylation is not absolutely
required for OL lineage progression (Figure S4).
To examine OLP-inducing activity further, we electroporated
Olig2WT or Olig2S147A expression vectors into chick neural
tube. It has been reported that Olig2WT can induce expression
of OLP markers in the dorsal neural tube, after a delay of around
4 days post-electroporation (Liu et al., 2007). We found that
forced expression of Olig2S147A induced dorsal SOX10 expres-
sion well ahead of this schedule at 48 hr post-electroporation
(Figures 5M and 5N). As expected, Olig2WT did not induce
SOX10 on this time scale (Figures 5K and 5L). Taken together,our data suggest that OL fate is favored, even accelerated,
when OLIG2 is not phosphorylated on S147.
OLIG2S147A Favors OL Lineage Development
in Cultured P19 Cells
To investigate further the role of OLIG2-S147 phosphorylation in
neural fate determination, we turned to an in vitro assay using
P19 cells. This pluripotent embryonal carcinoma (EC)-derived
cell line can differentiate into different cell lineages under appro-
priate inductive conditions (Jones-Villeneuve et al., 1982, 1983).
For example, cell aggregation together with retinoic acid (RA)
treatment drives the differentiation of P19 cells toward a neural
fate, even as early as 4 hr postinduction (Berg and McBurney,
1990; Staines et al., 1996). We treated aggregated P19 cells
with RA together with the SHH small-molecule agonist
SHHAg1.2, a combination that can initiate MN development in
cultured embryonic stem (ES) cells (Wichterle et al., 2002). We
found that RA/SHHAg1.2 also induced the MN marker HB9 in
aggregated P19 cells (Figures 6A and 6B). Furthermore, this
treatment induced expression of proteoglycan NG2, which
marks OLPs (Figures 6E and 6F).
To study the influence of OLIG2 on neural differentiation of
P19 cells, we constructed two stable P19 lines that constitutively
expressed V5-tagged OLIG2WT or OLIG2S147A. Without
RA/SHHAg1.2 induction, both cell lines grew and behaved like
the parent P19 line. With RA/SHHAg1.2 induction, the P19-
OLIG2WT line produced significantly increased numbers of
HB9-positive cells (p < 0.001) and NG2-positive cells (p < 0.05)
compared to induced P19 control cells (Figures 6C and 6G).
This is in keeping with previous reports that constitutive expres-
sion of OLIG2WT can enhance the output of MNs and OL lineage
cells from ES cells (Du et al., 2006; Shin et al., 2007). Under
inducing conditions P19-OLIG2S147A cultures developed
a decreased number of HB9-positive cells (p < 0.05) compared
with control P19 cells (Figure 6D), demonstrating a dominant-
negative effect of the S147A mutant protein over endogenous,
wild-type OLIG2 (which is also present in the P19 lines). Strik-
ingly, P19-OLIG2S147A cells induced with RA/SHHAg1.2 gener-
ated many more NG2-positive cells compared to induced P19-
OLIG2WT (p < 0.001) or parental P19 (p < 0.001) lines (Figures
6F–6J). The induced NG2-positive cells also expressed SOX10
(Figure 6I) and MBP (Figure S5). These data provide strong
confirmation that loss of OLIG2-S147 phosphorylation directs
NSCs away from an MN fate toward the OL lineage.
DISCUSSION
We have shown that phosphorylation of OLIG2 on S147 is
required for the early functions of OLIG2 in neuroepithelial
patterning andMN specification but is subsequently dispensable
forOLPspecification.Wehave also shown thatS147 is phosphor-
ylated duringMN specification in the ventral spinal cord, dephos-
phorylated at the onset of OLP production, and that that dephos-
phorylation switches the binding preference of OLIG2 away from
OLIG1/2 toward NGN2.We believe that this represents a key part
of the regulatory mechanism that operates through OLIG2 to
switch NSC fate from MNs to OLPs during ventral spinal cord
development. Other phosphorylation events might also beNeuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc. 923
Figure 6. OLIG2S147A Promotes OL Fate
Specification but Represses MN Fate in
Cultured P19 Cells
(A–D) MN induction: addition of SHHAg1.2 agonist
and RA induced aggregated P19 cells to express
the MN marker HB9 (B and B0). This induction
was accentuated in stable cell line P19-OLIG2WT
(C and C0) but repressed in P19-OLIG2S147A
(D and D0).
(E–H) OL induction: SHHAg1.2 and RA also
induced aggregated P19 cells to express OLP
marker NG2 (F and F0). This induction was slightly
amplified in the P19-OLIG2WT line (G and G0)
but dramatically magnified in P19-OLIG2S147A
(H and H0 ).
(I, I0, and I00) The NG2-positive cells (green) that
were induced in P19-OLIG2S147A cultures also ex-
pressed SOX10 (red), confirming them as OL
lineage cells. Cell nuclei were counterstained
with DAPI (blue).
(J) Quantification of HB9 and NG2-inducing
activity.
Scale bar, 50 mm (A–H0 and I–I00). See also
Figure S5.
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OLIG2 Phosphorylation and the Neuron-Glial Switchimportant for the functional regulation of OLIG2, e.g., it was
recently shown that caseinkinase2 (CK2)-mediatedphosphoryla-
tion is required for the oligodendrogenic activity ofOLIG2 (Huillard
et al., 2010). Serine phosphorylation of NGN2 by glycogen syn-
thase kinase-3 (GSK3) hasalsobeen shown topromoteMNspec-
ification by facilitating assembly of NGN2 into a transcriptional
complex with homeodomain factors LHX3 and ISL1/2 (Ma et al.,
2008). It seems that phosphorylation of bHLH proteins (and
perhaps other posttranslational modifications) might be
a common means of regulating cell fate and lineage progression.
OLIG2-S147 Phosphorylation and the MN-OL Fate
Switch
Our data reveal that gain or loss of a phosphate group on OLIG2-
S147 goes hand in hand with MN or OL generation, respectively.924 Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc.In our Olig2S147A mice, the pMN domain
was transformed mainly to p2, and
consequently, MN development was
blocked. This does not reflect a global
loss of OLIG2 function because expres-
sion studies in Cos-7 cells demonstrated
that OLIG2S147A is a stable protein that is
indistinguishable from OLIG2WT by
mobility on sodium dodecyl sulfate
(SDS)-PAGE, subcellular localization, or
its ability to bind known transcriptional
partners such as SOX10 or NKX2.2.
Most importantly, OLIG2S147A did not
lose its ability to specify OL lineage cells,
although fewer OLPs than normal devel-
oped in the spinal cords of Olig2S147A
mice, and these were delayed, appearing
at E15.5–17.5 instead of E12.5 as in wild-
type cord. This fits with the fact that thepMN progenitor domain, which normally produces 80% of all
OLPs in the cord, is lost in the mutant. The remaining 20% of
OLPs are produced frommore dorsal progenitor domains, which
do not depend on the neuroepithelial patterning function of
OLIG2 (Cai et al., 2005; Fogarty et al., 2005; Vallstedt et al.,
2005). These dorsally derived OLPs are generated later than
pMN-derived OLPs (E16.5 versus E12.5). They still require
OLIG2 function for their development, for in Olig2/ mice there
are no spinal OLPs whatsoever (Lu et al., 2002; Takebayashi
et al., 2002). It is very likely that the late-forming OLPs found in
the Olig2S147A mutant correspond to these dorsally derived
OLPs. The fact that they arise in the mutant demonstrates that
the OLP-inducing function of OLIG2 is separable and distinct
from its neuroepithelial patterning and MN-inducing functions.
This conclusion is reinforced by the observation that Olig2S147A
Figure 7. A Model of How OLIG2 Might Sequentially Regulate MN
and OLP Fates through Reversible Phosphorylation on S147
A key feature is that dephosphorylation of OLIG2 increases the efficiency of
OLIG2-NGN2 heterodimer formation, reducing the amount of NGN2 available
for activating MN-specific genes and thereby contributing to the neuron-OL
fate switch.
Neuron
OLIG2 Phosphorylation and the Neuron-Glial Switchcannot induce ectopic MNs in chick electroporation experi-
ments, yet can still induce the OL lineage marker Sox10. More-
over, Olig2S147A induces Sox10 on an accelerated time course
compared to Olig2WT, suggesting that Olig2S147A instructs
NSCs to ‘‘leapfrog’’ MN production and go straight to OLPs.
This separation between the MN- and OLP-inducing functions
of OLIG2 was also strikingly confirmed by cell culture experi-
ments; P19 cells (NSC-like) stably transfected with anOlig2S147A
expression vector generated many more OL lineage cells—both
NG2+ OLPs and MBP+ OLs—and less HB9+ MNs than did P19
cells stably transfectedwithOlig2WT. TheMBP+ cells that formed
in these experiments did not adopt the multiprocess-bearing
morphology typical of normal OLs in culture, so other factors in
addition to OLIG2 are presumably required for full OL differenti-
ation of P19 cells.
We found that OLIG2S147A has an enhanced ability to bind
NGN2, coupledwith a diminished ability to form dimers with itself
or OLIG1. Consistent with this, we found that OLIG2S147A inhibits
NGN2-mediated transcriptional activation of the HB9 promoter
more efficiently than does OLIG2WT, in cotransfection assays
with an HB9:luciferase reporter (Figure S6). NGN2 is a bHLH
transcription factor that is known to be required for MN develop-
ment because spinal MNs are not formed properly in mice lack-
ing NGN2 (Scardigli et al., 2001). OLIG2 and NGN2 are coex-
pressed in the pMN domain and nowhere else, implying that
OLIG2 and NGN2 act in concert during MN development (Mizu-
guchi et al., 2001; Novitch et al., 2001). There is evidence that
OLIG2/NGN2 coexpression drives NSCs to exit the cell cycle
and start expressing pan-neuronal markers (Mizuguchi et al.,
2001; Novitch et al., 2001; Lee et al., 2005). NGN2 expression
is later downregulated in pMN, and this was suggested to be
necessary to enable pMN progenitors to switch from MN to
OLP production (Zhou et al., 2001). However, in the light of our
current data, we believe that NGN2 downregulation is not the
trigger but rather a consequence of theMN-OLP switch that rein-
forces and stabilizes the gliogenic state.
Taken together with previous research, our data provide new
ideas about the chain of events leading up to and beyond the
MN-OLP fate switch. We propose that during the early neuro-
genic phase (E9–E12), homodimers of S147-phosphorylated
OLIG2 act to repress OL lineage genes in pMN and create
a permissive environment for MN development—in which
NGN2 plays an important role in concert with homeodomain
transcription factors ISL1/2 and LHX3 (Lee and Pfaff, 2003;
Lee et al., 2005; Ma et al., 2008). Subsequently, dephosphoryla-
tion of OLIG2-S147 disrupts OLIG2 homodimers and encour-
ages formation of heterodimers such as OLIG2/NGN2, thereby
sequestering NGN2 and possibly other bHLH factors and shut-
ting down MN lineage genes. At the same time, OLIG2 associ-
ates with other unidentified cofactors to activate the OL genetic
program and repress the MN program (including NGN2), hence
reinforcing the neuron-glial switch. This scheme is illustrated in
Figure 7. However, we note that endogenous MN development
did not appear to be inhibited in OLIG2S147A:OLIG2+/ mice
(data not shown) or in OLIG2S147A-electroporated chick (Fig-
ure 4L), which could be taken to argue against the simple
sequestration model depicted. However, it is possible that in
both these situations OLIG2S147A expression might not havebeen robust enough to completely overcome endogenous
OLIG2 function.
A potential partner of OLIG2 that might come into play during
OL lineage specification is NKX2.2. Forced expression of OLIG2
together with NKX2.2 in chick neural tube induces early onset of
OLP specification (Sun et al., 2001). In addition, OLIG2 and
NKX2.2 can physically interact with each other (Sun et al.,
2003). However, OLIG2 and NKX2.2 are not tightly colocalized
in the pMN domain in the run up to MN-OLP fate switching in
mice (Sun et al., 1998; Richardson et al., 2006), so it is not clear
that OLIG2 and NKX2.2 normally work together in OLP specifica-
tion. In fact, OLPs develop normally in NKX2.2 null mice,
although their subsequent differentiation into OLs is prevented
(Qi et al., 2001). Another potential cofactor for OLIG2 is
MASH1/ASCL1; initially (E12.5) there are reduced numbers of
OLPs in MASH1 null spinal cords, but this soon resolves, sug-
gesting thatMASH1 is not critical for OLP specification (Sugimori
et al., 2008).We found that S147Amutation did not have a notice-
able effect on binding of OLIG2 to either NKX2.2 or MASH1 (Fig-
ure S2A), so we probably have to look elsewhere for critical
determinants of OL lineage specification in the spinal cord. The
transcription factor NF1A has been proposed to trigger gliogen-
esis throughout the neural tube (Deneen et al., 2006), but its
physical and functional relationships with OLIG2 have yet to be
investigated. Recently, OLIG2 was shown to interact with the
bHLH protein E47 to directly activate the Sox10-U2 promoter
in the OL lineage (Ku¨spert et al., 2010). The results of our present
study suggest that dephosphorylated OLIG2S147 might specifi-
cally interact with E47 in this context.
Epigenetic modifications play an important part in cell fate
decisions, including OLP specification. For example, in theNeuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc. 925
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OLIG2 Phosphorylation and the Neuron-Glial Switchabsence of histone deacetylases 1 and/or 2 (HDAC1/2), OLP
formation in the ventral spinal cord is disrupted (Cunliffe and
Casaccia-Bonnefil, 2006; Ye et al., 2009; Li et al., 2009). It will
be important in the future to investigate the potential interactions
between OLIG2, HDACs, and other histone modifiers (e.g.,
methylases) and how these interactions might be influenced by
posttranslational modification.
The Role of PKA
Our study focused on reversible phosphorylation of OLIG2-
S147, an evolutionarily conserved site that is predicted to be
a PKA target. We provided evidence that OLIG2-S147 can be
phosphorylated by PKA in cultured Cos-7 cells and that dnPKA
inhibits phosphorylation. Despite this, we cannot conclude that
PKA is the only—or even the primary—protein serine kinase to
target S147 in vivo. For example, the consensus target sequence
for PKA (R[R/K]X[S/T]) can overlap with that of PKC ([R/K]X[S/T]U
[R/K]) (U, hydrophobic). Indeed, PKA and PKC are thought to
phosphorylate common acceptor sites on the bHLH proteins
HAND1 and HAND2 (Firulli et al., 2003).
Nevertheless, the fact that Olig2S147A mice failed to develop
MNs suggests that PKA might normally play a positive role in
MN development. This seems counter to the popular idea that
PKA negatively regulates the SHH pathway (Li et al., 1995;
Ruiz i Altaba, 1999; Epstein et al., 1996; Hammerschmidt et al.,
1996; Jacob and Briscoe, 2003). SHH signaling works through
the transcription factors GLI1–3, vertebrate homologs of
Drosophila Cubitus interruptus (Ci). SHH activates GLI3 (and
GLI2) by inducing its proteolytic conversion from a full-length
transcriptional activator into a truncated N-terminal repressor
(Ruppert et al., 1990; Dai et al., 1999; Wang et al., 2000). It is
believed that PKA phosphorylation stimulates GLI3 cleavage
(Wang et al., 2000; Tempe et al., 2006), which might underlie
the repressive action of PKA on SHH signaling since truncated
GLI3 represses the SHH pathway (Dai et al., 1999; Wang et al.,
2000; Bai et al., 2004; Tempe et al., 2006). GLI3 is not the only
component of the SHH pathway that can be PKA phosphory-
lated, and PKA has been shown to play a positive as well as
a negative role in SHH signaling. For example, in Drosophila,
PKA phosphorylation of SMO, the Hedgehog (HH) coreceptor,
promotes SMO accumulation on the primary cilium and triggers
HH pathway activation (Jia et al., 2004). Also, during limb devel-
opment, elevating PKA activity by Forskolin treatment or by in-
fecting with a retroviral PKA expression vector exerts a positive
effect on SHH signaling, resulting in an altered pattern of digits
(Tiecke et al., 2007).
We examined the effect of stimulating the PKA pathway in
neonatal mouse cortical cell cultures with Forskolin and dibu-
tyryl cyclic AMP (db-cAMP), a cell-permeable analog of
cAMP, and found that the number of NG2-positive OLPs was
significantly decreased compared to untreated cultures (Fig-
ure S7). This is consistent with expectation since our other
data predict that elevating PKA activity should increase
OLIG2-S147 phosphorylation and stimulate neurogenesis at
the expense of OLPs. However, in the light of the above discus-
sion, it is clear that PKA probably has multiple parallel functions,
and our experiments with Forskolin/db-cAMP should be inter-
preted cautiously.926 Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc.What Signals S147 Dephosphorylation?
Our data raise the obvious question: What is the key event that
signals S147 dephosphorylation and triggers the MN-OLP
switch in pMN? Notch signaling is known to play an important
role in glial cell development in the CNS (Wang et al., 1998;
Park and Appel, 2003; Park et al., 2005; Deneen et al., 2006).
Constitutive activation of components of the Notch pathway in
chick spinal cord can downregulate NGN2 expression in pMN
and initiate OLP generation (Zhou et al., 2001). Notch1 is ex-
pressed by neuroepithelial cells throughout the neural tube,
and its ligand Jagged-2 is expressed exclusively in the pMN
domain of zebrafish spinal cord during late neurogenesis (Yeo
and Chitnis, 2007). These and other observations frame the
Notch pathway as a potential key player in the MN-OLP switch.
It is possible that activated Notch-1, via its effector HES5, might
induce expression of specific phosphatases and/or repress
phosphatase inhibitors, resulting in dephosphorylation of
OLIG2-S147 and initiation of OLP production. It will be worth
exploring these ideas in the future. By improving our under-
standing of OL lineage specification, this work might aid the
design of procedures for efficient large-scale production of OL
lineage cells for clinical use—cell replacement therapy for demy-
elinating diseases like multiple sclerosis, for example—or for
high-throughput drug screens. Study of the posttranslational
pathways that modulate transcriptional activity of OLIG2,
NGN2 and other related factors might also provide insights into
general mechanisms of stem cell fate choice.EXPERIMENTAL PROCEDURES
Plasmid Vectors
Open reading frames of mouse Olig1, Olig2, Sox10, Ngn2,Mash1, and Nkx2.2
were amplified by RT-PCR from RNA extracted from mouse embryonic spinal
cord tissue and subcloned into Invitrogen’s pCDNA3.1-V5 and/or pCDNA4-
myc vectors, or Promega’s pBIND and/or pACT vectors (for two-hybrid
assays). Catalytic PKA and dnPKA vectors were kindly provided by Dr. Judy
Varner (University of California, San Diego). S147Amutant vectors were gener-
ated using Stratagene’s QuikChange Site-Directed Mutagenesis Kit following
the manufacturer’s instructions. The HB9- luciferase reporter plasmid HB9:luc
(Lee et al., 2005) was a gift from Dr. Samuel Pfaff (Salk Institute, La Jolla, CA,
USA).
Antibodies and In Situ Hybridization Probes
Primary antibodies used for WB and IP were as follows: goat anti-OLIG2 (R&D
Systems; used at 1:250 dilution for IP); rabbit anti-OLIG2 (a gift from Charles
Stiles, Dana Farber Cancer Institute; 1:20,000 for WB); mouse anti-Myc
(Sigma; 1:5,000 for WB); rabbit anti-Myc (Abcam; 1:500 for IP); and mouse
anti-V5 (Abcam; 1:2,500 for WB). The specific anti-OLIG2 ph-S147 antibody
was generated by CovalAb UK, Cambridge. The sequence of the immunizing
peptide was YAHGPSVRKL-(phospho-S147)-KIA (residues 137–150 of
OLIG2). Rabbits were immunized four times with peptide, and antiserum
was collected 25 days after the last injection. The antiserumwas first absorbed
on a column containing nonphosphorylated peptide and then affinity purified
on a phosphopeptide column. The purified antibody was used in WB at a dilu-
tion of 1:250. Primary antibodies used for immunofluorescence labeling were:
goat anti-OLIG2 (R&D Systems; 1:750); rabbit anti-OLIG2 (from Charles Stiles;
1:4000); chick anti-GFP (Aveslab; 1:1000); rabbit anti-V5 (Abcam; 1:250);
rabbit anti-Pax6 (Chemicon; 1:500); mouse anti-Nkx2.2 (Developmental
Studies Hybridoma Bank [DSHB] supernatant; 1:50); mouse anti-HB9
(DSHB; 1:20); guinea pig anti-SOX10 (a gift from Michael Wegner, Erlanger
University, Germany; 1:2000); and rat anti-PDGFRa (BD PharMingen; 1:400).
Secondary antibodies for WB were bought from Thermo Pierce and used at
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1:750 dilution). The in situ hybridization probes for mouse Sox10 and Pdgfra
were described previously (Tekki-Kessaris et al., 2001). The chick Sox10 probe
was generated by in vitro transcription from a plasmid containing a chick
Sox10 genomic fragment.
Mouse Lines
The Olig2 KO line was obtained from Charles Stiles (Dana Farber Cancer
Institute, Harvard Medical School) and David Rowitch (University of California,
San Francisco) (Lu et al., 2002). The Olig1/Olig2 double-null line (Olig1/,
Olig2GFP/GFP) was provided by David Anderson (California Institute of Tech-
nology) (Zhou and Anderson, 2002). To create Olig2WT and Olig2S147A trans-
genic lines, a mouse PAC clone containing a200 kbOlig2 genomic fragment
wasmodified by homologous recombination in E. coli (Lee et al., 2001). The 50-
homology fragments were subcloned into pCDNA3.1-Olig2WT-V5 or
pCDNA3.1-Olig2S147A-V5. The modified PAC constructs were linearized with
PvuI and purified by pulsed field gel electrophoresis for pronuclear injection.
Transgenic founders were screened by Southern blot of BglII-digested
genomic DNA, and single-copy founders were selected to establish lines.
The radiolabeled probe for Southern blotting detected a sequence in the
30UTR of the Olig2 gene. Progeny of transgenic founders were crossed first
with Olig2+/ mice (Lu et al., 2002) to obtain Olig2S147A:Olig2+/ and
Olig2WT:Olig2+/ offspring of both sexes, which were then sibling mated to
obtain Olig2S147A (i.e., Olig2S147A:Olig2/) and Olig2WT (Olig2WT:Olig2/)
offspring for analysis. For certain experiments (e.g., Figure S3), we crossed
Olig2S147A:Olig2+/ or Olig2WT:Olig2+/ animals to Olig1/2 double knockouts,
which express GFP under control of the Olig2 locus (Zhou and Anderson,
2002), to obtain Olig2S147A:Olig2 GFP/, Olig1+/, and Olig2WT:Olig2 GFP/,
Olig1+/ embryos.
Cell Culture
Cos-7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (Invitrogen) at 37C with
5% (v/v) CO2. Plasmid transfection was performed using Lipofectamine
2000 reagent (Invitrogen). Total DNA concentrations were normalized with
empty vector DNA where required. The P19 EC-derived cell line was
purchased from LGC-ATCC and maintained in Alpha minimal essential
medium with ribonucleosides and deoxyribonucleosides, supplemented with
5% fetal bovine serum (Invitrogen) at 37C with 5% CO2. For differentiation
assays, 5 3 104 P19 cells were plated on 35 mm diameter plates in medium
with 1% serum. After 5–6 days, the aggregated cells were treated with 1 mM
RA and 100 nM SHHAg1.2 (Curis, Inc.). Cells were fixed for immunolabeling
after two more days in culture.
IP and WBs
Cultured cells were lysed by homogenization in 50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, and
one tablet of protease inhibitor mix per 50 ml buffer. Lysis buffer for spinal
cord tissue was purchased from Sigma (CelLytic MT); sometimes phospha-
tase inhibitors were included. After lysis, cell debris was removed by centrifu-
gation at 30,000 3 g, then 500 ml cell lysate was treated with 50 U of DNase1
and precleared with 30 ml of protein G beads (GE Healthcare) for 3 hr at 4C on
a rotating wheel. The supernatant was decanted, incubated with the antibody
of interest at 4C for 1 hr, mixed with 30 ml of protein G beads, and incubated
overnight at 4C. The beads were washed twice in lysis buffer, twice in high-
salt buffer (50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1% [v/v] Nonidet P-40,
0.05% [w/v] sodium deoxycholate) and once in low-salt buffer (50 mM Tris-
HCl [pH 7.5], 0.1% Nonidet P-40, 0.05% sodium deoxycholate). The beads
were resuspended in 30 ml of SDS gel sample buffer, boiled for 5 min, and sub-
jected to SDS-PAGE followed by WB. Band intensity was quantified using Im-
ageJ software. For 2D PAGE the beads were treated with Invitrogen ZOOM
Protein Solubilizer, and protein samples were separated on the Invitrogen
ZOOM 2D gel system following the manufacturer’s instructions. After electro-
phoresis, proteins were transferred to polyvinylidene difluoride membranes.
Protein bands were visualized by chemiluminescence (ECLplus kit; GE
Healthcare).In Vitro Phosphorylation Assays
Thirty-six hours after transfection, Cos-7 cells were washed twice with phos-
phate-free DMEM (Invitrogen). Thirty mega-becquerels [33P]orthophosphate
(Amersham) were added to phosphate-free medium, and cells incubated for
4 hr at 37C. The medium was then removed, and the cells washed twice
with ice-cold PBS and immediately lysed on ice (see above). Proteins were
immunoprecipitated, separated by SDS-PAGE, and visualized by
autoradiography.
Two-Hybrid Protein Binding Assays
Two-hybrid assays for protein-protein interactions were performed using Dual
Luciferase Assay System (Promega). The amounts of transfected DNAs were
normalized with empty pCDNA vector. The measured firefly luciferase activity
was normalized against Renilla Luciferase activity. Three independent trans-
fections were conducted in parallel for each condition, and each experiment
was repeated three times.
In Ovo Electroporation of Chick Embryos
Fertilized chicken eggs were supplied by Henry Stuart Inc. and incubated at
38C in a humidified atmosphere. The embryos were staged according to
HH and electroporated at HH12–14 (Hamburger and Hamilton, 1992). Expres-
sion constructs were diluted in injection buffer (3 mg/ml in PBS containing 0.8%
[w/v] Fast Green), injected into the spinal cord lumen, and electroporated using
an Intracel TSS20 Ovodyne electroporator with EP21 current amplifier.
Embryos were analyzed 48 hr later.
Immunohistochemistry and In Situ Hybridization
Mouse and chick embryos were dissected in cold PBS and fixed in 4% (w/v)
paraformaldehyde (PFA) in PBS for 1 hr at 20C or overnight at 4C (for
SOX10 immunolabeling). The tissues were cryoprotected with 20% (w/v)
sucrose in PBS, embedded in OCT, and frozen for cryosectioning. Tissue
sections (15 mm) were permeabilized and preblocked in 0.1% (v/v) Triton
X-100, 2% (v/v) calf serum in PBS for 1 hr at 20C, then incubated in primary
antibodies diluted in 2% calf serum in PBS overnight at 4C followed by
secondary antibodies at 20C for 1 hr. Sections were counterstained with
Hoescht 33258 (1:1000; Sigma) to visualize cell nuclei. For RNA in situ hybrid-
ization, see http://www.ucl.ac.uk/ucbzwdr/Richardson.htm.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
doi:10.1016/j.neuron.2011.01.030.
ACKNOWLEDGMENTS
We thank our colleagues in the Wolfson Institute for Biomedical Research,
particularly Marta del Barrio and Raquel Taveira-Marques, for helpful advice
and discussions. We gratefully acknowledge Nicoletta Kessaris for help with
triple-label immunofluorescence (Figure 4A) and Richa Tripathi for confocal
micrography (Figure 5). We thank Ulla Dennehy, Matthew Grist, Helin Zhuang,
and Sabrina Pacheco for technical assistance, Michael Wegner and Charles
Stiles for providing antibodies, Judy Varner for PKA and dnPKA expression
vectors, Samuel Pfaff for the HB9-luciferase reporter, and David Rowitch
and David Anderson for Olig null mice. The work was funded by grants from
the UK Medical Research Council and The Wellcome Trust.
Accepted: January 28, 2011
Published: March 9, 2011
REFERENCES
Arnett, H.A., Fancy, S.P., Alberta, J.A., Zhao, C., Plant, S.R., Kaing, S., Raine,
C.S., Rowitch, D.H., Franklin, R.J., and Stiles, C.D. (2004). bHLH transcription
factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306,
2111–2115.Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc. 927
Neuron
OLIG2 Phosphorylation and the Neuron-Glial SwitchBai, C.B., Stephen, D., and Joyner, A.L. (2004). All mouse ventral spinal cord
patterning by hedgehog is Gli dependent and involves an activator function
of Gli3. Dev. Cell 6, 103–115.
Berg, R.W., and McBurney, M.W. (1990). Cell density and cell cycle effects on
retinoic acid-induced embryonal carcinoma cell differentiation. Dev. Biol. 138,
123–135.
Blom, N., Gammeltoft, S., and Brunak, S. (1999). Sequence and structure-
based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol.
294, 1351–1362.
Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., and Brunak, S.
(2004). Prediction of post-translational glycosylation and phosphorylation of
proteins from the amino acid sequence. Proteomics 4, 1633–1649.
Briscoe, J., Pierani, A., Jessell, T.M., and Ericson, J. (2000). A homeodomain
protein code specifies progenitor cell identity and neuronal fate in the ventral
neural tube. Cell 101, 435–445.
Cai, J., Qi, Y., Hu, X., Tan, M., Liu, Z., Zhang, J., Li, Q., Sander, M., and Qiu, M.
(2005). Generation of oligodendrocyte precursor cells from mouse dorsal
spinal cord independent of Nkx6 regulation and Shh signaling. Neuron 45,
41–53.
Cunliffe, V.T., and Casaccia-Bonnefil, P. (2006). Histone deacetylase 1 is
essential for oligodendrocyte specification in the zebrafish CNS. Mech. Dev.
123, 24–30.
Dai, P., Akimaru, H., Tanaka, Y., Maekawa, T., Nakafuku, M., and Ishii, S.
(1999). Sonic Hedgehog-induced activation of the Gli1 promoter is mediated
by GLI3. J. Biol. Chem. 274, 8143–8152.
Deneen, B., Ho, R., Lukaszewicz, A., Hochstim, C.J., Gronostajski, R.M., and
Anderson, D.J. (2006). The transcription factor NFIA controls the onset of glio-
genesis in the developing spinal cord. Neuron 52, 953–968.
Du, Z.W., Li, X.J., Nguyen, G.D., and Zhang, S.C. (2006). Induced expression
of Olig2 is sufficient for oligodendrocyte specification but not for motoneuron
specification and astrocyte repression. Mol. Cell. Neurosci. 33, 371–380.
Epstein, D.J., Marti, E., Scott, M.P., and McMahon, A.P. (1996). Antagonizing
cAMP-dependent protein kinase A in the dorsal CNS activates a conserved
Sonic hedgehog signaling pathway. Development 122, 2885–2894.
Firulli, B.A., Howard, M.J., McDaid, J.R., McIlreavey, L., Dionne, K.M.,
Centonze, V.E., Cserjesi, P., Virshup, D.M., and Firulli, A.B. (2003). PKA,
PKC, and the protein phosphatase 2A influenceHAND factor function: amech-
anism for tissue-specific transcriptional regulation. Mol. Cell 12, 1225–1237.
Fogarty, M., Richardson, W.D., and Kessaris, N. (2005). A subset of oligoden-
drocytes generated from radial glia in the dorsal spinal cord. Development 132,
1951–1959.
Fogarty, M.H. (2006) Fate-mapping the mouse neural tube by Cre-loxP trans-
genesis. Doctoral thesis, University of London, London, UK. http://www.ucl.
ac.uk/ucbzwdr/Pubs.htm.
Hamburger, V., and Hamilton, H.L. (1992). A series of normal stages in the
development of the chick embryo. 1951. Dev. Dyn. 195, 231–272.
Hammerschmidt, M., Bitgood,M.J., andMcMahon, A.P. (1996). Protein kinase
A is a common negative regulator of Hedgehog signaling in the vertebrate
embryo. Genes Dev. 10, 647–658.
Helms, A.W., and Johnson, J.E. (2003). Specification of dorsal spinal cord
interneurons. Curr. Opin. Neurobiol. 13, 42–49.
Huillard, E., Ziercher, L., Blond, O., Wong, M., Deloulme, J.C., Souchelnytskyi,
S., Baudier, J., Cochet, C., and Buchou, T. (2010). Disruption of CK2beta in
embryonic neural stem cells compromises proliferation and oligodendrogene-
sis in the mouse telencephalon. Mol. Cell. Biol. 30, 2737–2749.
Jacob, J., and Briscoe, J. (2003). Gli proteins and the control of spinal-cord
patterning. EMBO Rep. 4, 761–765.
Jessell, T.M. (2000). Neuronal specification in the spinal cord: inductive signals
and transcriptional codes. Nat. Rev. Genet. 1, 20–29.
Jia, J., Tong, C., Wang, B., Luo, L., and Jiang, J. (2004). Hedgehog signalling
activity of Smoothened requires phosphorylation by protein kinase A and
casein kinase I. Nature 432, 1045–1050.928 Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc.Jones-Villeneuve, E.M., McBurney, M.W., Rogers, K.A., and Kalnins, V.I.
(1982). Retinoic acid induces embryonal carcinoma cells to differentiate into
neurons and glial cells. J. Cell Biol. 94, 253–262.
Jones-Villeneuve, E.M., Rudnicki, M.A., Harris, J.F., and McBurney, M.W.
(1983). Retinoic acid-induced neural differentiation of embryonal carcinoma
cells. Mol. Cell. Biol. 3, 2271–2279.
Ku¨spert, M., Hammer, A., Bo¨sl, M.R., and Wegner, M. (2010). Olig2 regulates
Sox10 expression in oligodendrocyte precursors through an evolutionary
conserved distal enhancer. Nucleic Acids Res., in press. Published online
October 19, 2010. 10.1093/nar/gkq951.
Lee, E.C., Yu, D., Martinez de Velasco, J., Tessarollo, L., Swing, D.A., Court,
D.L., Jenkins, N.A., and Copeland, N.G. (2001). A highly efficient Escherichia
coli-based chromosome engineering system adapted for recombinogenic tar-
geting and subcloning of BAC DNA. Genomics 73, 56–65.
Lee, S.K., and Pfaff, S.L. (2003). Synchronization of neurogenesis and motor
neuron specification by direct coupling of bHLH and homeodomain transcrip-
tion factors. Neuron 38, 731–745.
Lee, S.K., Lee, B., Ruiz, E.C., and Pfaff, S.L. (2005). Olig2 and Ngn2 function in
opposition to modulate gene expression in motor neuron progenitor cells.
Genes Dev. 19, 282–294.
Li, H., He, Y., Richardson, W.D., and Casaccia, P. (2009). Two-tier transcrip-
tional control of oligodendrocyte differentiation. Curr. Opin. Neurobiol. 19,
479–485.
Li, H., Lu, Y., Smith, H.K., and Richardson, W.D. (2007). Olig1 and Sox10
interact synergistically to drive myelin basic protein transcription in oligoden-
drocytes. J. Neurosci. 27, 14375–14382.
Li, W., Ohlmeyer, J.T., Lane, M.E., and Kalderon, D. (1995). Function of protein
kinase A in hedgehog signal transduction and Drosophila imaginal disc devel-
opment. Cell 80, 553–562.
Liu, Z., Hu, X., Cai, J., Liu, B., Peng, X., Wegner, M., and Qiu, M. (2007).
Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence
for reciprocal interactions and dosage-dependent mechanisms. Dev. Biol.
302, 683–693.
Lu, Q.R., Yuk, D., Alberta, J.A., Zhu, Z., Pawlitzky, I., Chan, J., McMahon, A.P.,
Stiles, C.D., and Rowitch, D.H. (2000). Sonic hedgehog-regulated oligoden-
drocyte lineage genes encoding bHLH proteins in the mammalian central
nervous system. Neuron 25, 317–329.
Lu, Q.R., Sun, T., Zhu, Z., Ma, N., Garcia, M., Stiles, C.D., and Rowitch, D.H.
(2002). Common developmental requirement for Olig function indicates
a motor neuron/oligodendrocyte connection. Cell 109, 75–86.
Ma, Y.C., Song, M.R., Park, J.P., Henry Ho, H.Y., Hu, L., Kurtev, M.V., Zieg, J.,
Ma, Q., Pfaff, S.L., and Greenberg, M.E. (2008). Regulation of motor neuron
specification by phosphorylation of neurogenin 2. Neuron 58, 65–77.
Mizuguchi, R., Sugimori, M., Takebayashi, H., Kosako, H., Nagao, M.,
Yoshida, S., Nabeshima, Y., Shimamura, K., and Nakafuku, M. (2001).
Combinatorial roles of olig2 and neurogenin2 in the coordinated induction of
pan-neuronal and subtype-specific properties of motoneurons. Neuron 31,
757–771.
Murre, C., McCaw, P.S., Vaessin, H., Caudy, M., Jan, L.Y., Jan, Y.N., Cabrera,
C.V., Buskin, J.N., Hauschka, S.D., and Lassar, A.B. (1989). Interactions
between heterologous helix-loop-helix proteins generate complexes that
bind specifically to a common DNA sequence. Cell 58, 537–544.
Novitch, B.G., Chen, A.I., and Jessell, T.M. (2001). Coordinate regulation of
motor neuron subtype identity and pan-neuronal properties by the bHLH
repressor Olig2. Neuron 31, 773–789.
Park, H.C., and Appel, B. (2003). Delta-Notch signaling regulates oligodendro-
cyte specification. Development 130, 3747–3755.
Park, H.C., Mehta, A., Richardson, J.S., and Appel, B. (2002). olig2 is required
for zebrafish primary motor neuron and oligodendrocyte development. Dev.
Biol. 248, 356–368.
Park, H.C., Boyce, J., Shin, J., and Appel, B. (2005). Oligodendrocyte specifi-
cation in zebrafish requires notch-regulated cyclin-dependent kinase inhibitor
function. J. Neurosci. 25, 6836–6844.
Neuron
OLIG2 Phosphorylation and the Neuron-Glial SwitchPringle, N.P., Yu, W.P., Guthrie, S., Roelink, H., Lumsden, A., Peterson, A.C.,
and Richardson, W.D. (1996). Determination of neuroepithelial cell fate: induc-
tion of the oligodendrocyte lineage by ventral midline cells and Sonic
hedgehog. Dev. Biol. 177, 30–42.
Qi, Y., Cai, J., Wu, Y., Wu, R., Lee, J., Fu, H., Rao, M., Sussel, L., Rubenstein,
J., and Qiu, M. (2001). Control of oligodendrocyte differentiation by the Nkx2.2
homeodomain transcription factor. Development 128, 2723–2733.
Richardson, W.D., Kessaris, N., and Pringle, N. (2006). Oligodendrocyte wars.
Nat. Rev. Neurosci. 7, 11–18.
Richardson,W.D., Smith, H.K., Sun, T., Pringle, N.P., Hall, A., andWoodruff, R.
(2000). Oligodendrocyte lineage and the motor neuron connection. Glia 29,
136–142.
Rowitch, D.H. (2004). Glial specification in the vertebrate neural tube. Nat. Rev.
Neurosci. 5, 409–419.
Rowitch, D.H., Lu, Q.R., Kessaris, N., and Richardson, W.D. (2002). An
‘oligarchy’ rules neural development. Trends Neurosci. 25, 417–422.
Ruiz i Altaba, A. (1999). Gli proteins encode context-dependent positive and
negative functions: implications for development and disease. Development
126, 3205–3216.
Ruppert, J.M., Vogelstein, B., Arheden, K., and Kinzler, K.W. (1990). GLI3
encodes a 190-kilodalton protein with multiple regions of GLI similarity. Mol.
Cell. Biol. 10, 5408–5415.
Scardigli, R., Schuurmans, C., Gradwohl, G., and Guillemot, F. (2001).
Crossregulation between Neurogenin2 and pathways specifying neuronal
identity in the spinal cord. Neuron 31, 203–217.
Shen, Q., Wang, Y., Dimos, J.T., Fasano, C.A., Phoenix, T.N., Lemischka, I.R.,
Ivanova, N.B., Stifani, S., Morrisey, E.E., and Temple, S. (2006). The timing of
cortical neurogenesis is encoded within lineages of individual progenitor cells.
Nat. Neurosci. 9, 743–751.
Shin, S., Xue, H., Mattson, M.P., and Rao, M.S. (2007). Stage-dependent Olig2
expression in motor neurons and oligodendrocytes differentiated from embry-
onic stem cells. Stem Cells Dev. 16, 131–141.
Staines, W.A., Craig, J., Reuhl, K., and McBurney, M.W. (1996). Retinoic acid
treated P19 embryonal carcinoma cells differentiate into oligodendrocytes
capable of myelination. Neuroscience 71, 845–853.
Sugimori, M., Nagao, M., Parras, C.M., Nakatani, H., Lebel, M., Guillemot, F.,
and Nakafuku, M. (2008). Ascl1 is required for oligodendrocyte development in
the spinal cord. Development 135, 1271–1281.
Sun, T., Pringle, N.P., Hardy, A., Richardson, W.D., and Smith, H.K. (1998).
Pax6 influences the time and site of origin of glial precursors in the ventral
neural tube. Mol. Cell. Neurosci. 12, 228–239.
Sun, T., Echelard, Y., Lu, R., Yuk, D.I., Kaing, S., Stiles, C.D., and Rowitch, D.H.
(2001). Olig bHLH proteins interact with homeodomain proteins to regulate cell
fate acquisition in progenitors of the ventral neural tube. Curr. Biol. 11, 1413–
1420.
Sun, T., Dong, H., Wu, L., Kane, M., Rowitch, D.H., and Stiles, C.D. (2003).
Cross-repressive interaction of the Olig2 and Nkx2.2 transcription factors in
developing neural tube associated with formation of a specific physical
complex. J. Neurosci. 23, 9547–9556.
Takebayashi, H., Yoshida, S., Sugimori, M., Kosako, H., Kominami, R.,
Nakafuku, M., and Nabeshima, Y. (2000). Dynamic expression of basic helix-
loop-helix Olig family members: implication of Olig2 in neuron and oligoden-drocyte differentiation and identification of a new member, Olig3. Mech.
Dev. 99, 143–148.
Takebayashi, H., Nabeshima, Y., Yoshida, S., Chisaka, O., Ikenaka, K., and
Nabeshima, Y. (2002). The basic helix-loop-helix factor olig2 is essential for
the development of motoneuron and oligodendrocyte lineages. Curr. Biol.
12, 1157–1163.
Tekki-Kessaris, N., Woodruff, R., Hall, A.C., Gaffield, W., Kimura, S., Stiles,
C.D., Rowitch, D.H., and Richardson, W.D. (2001). Hedgehog-dependent
oligodendrocyte lineage specification in the telencephalon. Development
128, 2545–2554.
Tempe, D., Casas, M., Karaz, S., Blanchet-Tournier, M.F., and Concordet, J.P.
(2006). Multisite protein kinase A and glycogen synthase kinase 3beta phos-
phorylation leads to Gli3 ubiquitination by SCFbetaTrCP. Mol. Cell. Biol. 26,
4316–4326.
Tiecke, E., Turner, R., Sanz-Ezquerro, J.J., Warner, A., and Tickle, C. (2007).
Manipulations of PKA in chick limb development reveal roles in digit patterning
including a positive role in Sonic Hedgehog signaling. Dev. Biol. 305, 312–324.
Vallstedt, A., Klos, J.M., and Ericson, J. (2005). Multiple dorsoventral origins
of oligodendrocyte generation in the spinal cord and hindbrain. Neuron 45,
55–67.
Wang, B., Fallon, J.F., and Beachy, P.A. (2000). Hedgehog-regulated process-
ing of Gli3 produces an anterior/posterior repressor gradient in the developing
vertebrate limb. Cell 100, 423–434.
Wang, S., Sdrulla, A.D., diSibio, G., Bush, G., Nofziger, D., Hicks, C.,
Weinmaster, G., and Barres, B.A. (1998). Notch receptor activation inhibits
oligodendrocyte differentiation. Neuron 21, 63–75.
Wang, S.Z., Dulin, J., Wu, H., Hurlock, E., Lee, S.E., Jansson, K., and Lu, Q.R.
(2006). An oligodendrocyte-specific zinc-finger transcription regulator cooper-
ates with Olig2 to promote oligodendrocyte differentiation. Development 133,
3389–3398.
Wichterle, H., Lieberam, I., Porter, J.A., and Jessell, T.M. (2002). Directed
differentiation of embryonic stem cells into motor neurons. Cell 110, 385–397.
Wissmuller, S., Kosian, T., Wolf, M., Finzsch, M., and Wegner, M. (2006). The
high-mobility-group domain of Sox proteins interacts with DNA-binding
domains of many transcription factors. Nucleic Acids Res. 34, 1735–1744.
Xin, M., Yue, T., Ma, Z., Wu, F.F., Gow, A., and Lu, Q.R. (2005). Myelinogenesis
and axonal recognition by oligodendrocytes in brain are uncoupled in Olig1-
null mice. J. Neurosci. 25, 1354–1365.
Ye, F., Chen, Y., Hoang, T., Montgomery, R.L., Zhao, X.H., Bu, H., Hu, T.,
Taketo, M.M., van Es, J.H., Clevers, H., et al. (2009). HDAC1 and HDAC2 regu-
late oligodendrocyte differentiation by disrupting the beta-catenin-TCF inter-
action. Nat. Neurosci. 12, 829–838.
Yeo, S.Y., and Chitnis, A.B. (2007). Jagged-mediated Notch signaling main-
tains proliferating neural progenitors and regulates cell diversity in the ventral
spinal cord. Proc. Natl. Acad. Sci. USA 104, 5913–5918.
Zhou, Q., and Anderson, D.J. (2002). The bHLH transcription factors OLIG2
and OLIG1 couple neuronal and glial subtype specification. Cell 109, 61–73.
Zhou, Q., Wang, S., and Anderson, D.J. (2000). Identification of a novel family
of oligodendrocyte lineage-specific basic helix-loop-helix transcription
factors. Neuron 25, 331–343.
Zhou, Q., Choi, G., and Anderson, D.J. (2001). The bHLH transcription factor
Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2.
Neuron 31, 791–807.Neuron 69, 918–929, March 10, 2011 ª2011 Elsevier Inc. 929
